Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Can-Fite BioPharma Ltd. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 12 | 13 | +1 |
| Shares | 754.3K | 114.4K | −639.9K (−84.8%) |
| Value | $1.52M | $185.9K | −$1.33M (−87.7%) |
New holders (3)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BNP Paribas Arbitrage, SA | 25,185 | $40.9K | 0.00% |
| Kohmann Bosshard Financial Services, LLC | 3,401 | $5.53K | 0.00% |
| SBI Securities Co., Ltd. | 1 | $2 | 0.00% |
Sold out (2)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Armistice Capital, LLC | 650,000 | $1.31M |
| Avion Wealth | 100 | $0 |